Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Principal Investigator

Carl Landgren

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20211132
National Clinical Trials Identifier NCT04401020

Clinical Trial Summary

Primary Objective:
To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in
patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory
non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D)
Secondary Objectives:
- To characterize the safety profile of SAR442257
- To characterize the pharmacokinetics (PK) profile of SAR442257
- To evaluate the potential immunogenicity of SAR442257
- To assess preliminary evidence of antitumor activity


Phase

Phase 1


Funding Agency/Sponsor

Industrial


Disease

Myeloma


Enrollment Eligibility

Inclusion criteria :
Participant must be at least 18 years of age or of the country's legal age of majority if
the legal age is >18 years old, at the time of signing the informed consent.
Life expectancy of at least 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance
status ≤2.
RRMM patients:
must have received at least 3 prior lines of therapy including proteasome inhibitor (PI),
immunomodulatory agent (IMiD), and anti-CD38 mAb;
and must be refractory to anti-CD38 antibody (eg, daratumumab or isatuximab), characterized
by progression within 60 days of the last dose of anti-CD38, regardless of which line it
was given; and must be either relapsed or refractory to all established therapies with
known clinical benefit in RRMM where approved and available, or are intolerant to those
established therapies; based upon investigator's clinical judgement.
and must not be candidates for regimens known to provide clinical benefit based upon
investigator's clinical judgement.
Patients with RRMM must have measurable disease as per the following:
- Serum M protein ≥0.5 g/dL (≥5 g/L), or
- Urine M protein ≥200 mg/24 hours, or
- Serum free light chain (FLC) assay: involved FLC assay ≥10 mg/dL and an abnormal serum
FLC ratio (<0.26 or >1.65).
Patients with RR-NHL must be relapsed or refractory to all established therapies with known
clinical benefit where approved and available, or are intolerant to those established
therapies; based upon investigator's clinical judgement.
Patients with RR-NHL must have measurable disease of at least one lesion ≥1.5 cm as
documented by computed tomography (CT) scan, including the following subtype of disease:
- Diffuse large B-cell lymphoma (DLBCL).
- HGBCL with MYC and/or BCL2 and/or BCL6 rearrangement or HGBCL NOS,
- transformed follicular lymphoma (tFL),
- follicular lymphoma (FL),
- mantle cell lymphoma (MCL),
- marginal zone lymphoma (MZL),
- lymphoplasmacytic lymphoma,
- small lymphocytic lymphoma (SLL). Patients with RR-NHL subtype T cell lymphoma (TCL)
including the following subtype of disease: Nodal peripheral TCL including
angio-immunoblastic TCL (AITL), anaplastic large cell lymphoma (ALCL), adult T cell
leukemia-lymphoma, and peripheral TCL NOS (not otherwise specified). Peripheral TCL of
the innate immune system: breast implant ALCL, extranodal NK/TCL, enteropathy
associated TCL, monomorphic epitheliotropic intestinal TCL, and hepatosplenic TCL.
histopathologically confirmed mycosis fungoides or Sézary syndrome (cutaneous T cell
lymphoma [CTCL] stage IIB or greater according to the European Organization for
Research and Treatment of Cancer/International Society for Cutaneous Lymphomas
[EORTC-ISCL] consensus classification) at study entry with progressive, persistent, or
recurrent disease who have no available remaining standard therapeutic options (ie,
refractory) as determined by the Investigator.
Patients with lymphoma must have availability of lymphoma tissue for biomarker testing:
either archived tissue or a fresh biopsy as a part of screening. On-treatment biopsy (Cycle
2 or beyond) is also expected if disease location is in a superficial lymph node. For
post-CAR-T patients a fresh LN biopsy is expected if in a superficial node. For these
patients tissue materials should be made available for analysis during the study.
Excisional biopsy or resected tissue is required if clinically feasible; otherwise, core
needle biopsy is acceptable. Fine needle aspirates are not acceptable.
Patients with lymphoma must have a ≥50% left ventricular ejection fraction (LVEF) and no
pericardial effusion, as measured by echocardiogram (ECHO).
Contraceptive use by men or women should be consistent with local regulations regarding the
methods of contraception for those participating in clinical studies.
Exclusion criteria:
Diagnosed or treated for another malignancy within 3 years prior to enrollment, except for
basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy,
superficial bladder carcinoma or low risk prostate cancer.
Amyloidosis, chronic lymphocytic leukemia and prolymphocytic leukemia. Known central
nervous system (CNS) involvement by myeloma, lymphoma or other CNS disease such as
neurodegenerative condition or CNS movement disorder.
Has congestive heart failure (New York Heart Association) Grade ≥II; cardiomyopathy, active
ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically
significant arrhythmia requiring therapy including anticoagulants, or clinically
significant uncontrolled hypertension, QT interval corrected by the Fridericia method >480
msec (Grade ≥2). Acute myocardial infarction within 6 months before start of study
treatment.
Has active autoimmune disease including autoimmune hemolytic anemia, idiopathic
thrombocytopenic purpura, inflammatory bowel syndrome, pneumonitis or any chronic condition
requiring a higher corticosteroid systemic equivalent than prednisone 10 mg daily.
Clinically-not controlled chronic or ongoing infectious disease requiring treatment at the
time of first dose or within the 14 days before first dose.
Active hepatitis A, B, and C as defined below: active hepatitis A (defined as positive
IgM), active hepatitis B (defined as either positive hepatitis B surface antigen or
positive hepatitis B viral DNA test above the lower limit of detection of the assay, and
hepatitis B core antibodies), or C infection (defined as a known positive hepatitis C
antibody result and known quantitative hepatitis C [HCV] ribonucleic acid [RNA] results
greater than the lower limits of detection of the assay).
Known positivity for Human Immunodeficiency Virus (HIV). Unresolved toxicities from prior
anticancer therapy, defined as not having resolved to Common Terminology Criteria for
Adverse Events (CTCAE) version 5.0 Grade 1 or to levels dictated in the eligibility
criteria with the exception of Grade 1 peripheral neuropathy, alopecia or toxicities from
prior anticancer therapy that are considered irreversible (defined as having been present
and stable for >4 weeks) which may be allowed if they are not otherwise described in the
exclusion criteria.
Participant not suitable for participation, whatever the reason, as judged by the
Investigator, including medical or clinical conditions, or participants potentially at risk
of noncompliance to study procedures.
Sensitivity to any of the study interventions, or components thereof, or drug or other
allergy that, in the opinion of the Investigator, contraindicates participation in the
study.
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.


Contact Information

Phone Number 305-243-2647
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.